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inhibit IRF3 at a post activation step that requires
deubiquitination activity
Krystal Matthews1, Alexandra Schäfer2, Alissa Pham3,4 and Matthew Frieman1*Abstract
Background: The outcome of a viral infection is regulated by complex interactions of viral and host factors. SARS
coronavirus (SARS-CoV) engages and regulates several innate immune response pathways during infection. We
have previously shown that the SARS-CoV Papain-like Protease (PLpro) inhibits type I interferon (IFN) by inhibiting
IRF3 phosphorylation thereby blocking downstream Interferon induction. This finding prompted us to identify other
potential mechanisms of inhibition of PLpro on IFN induction.
Methods: We have used plasmids expressing PLpro and IRF3 including an IRF3 mutant that is constitutively active,
called IRF3(5D). In these experiments we utilize transfections, chromatin immunoprecipitation, Electro-mobility Shift
Assays (EMSA) and protein localization to identify where IRF3 and IRF3(5D) are inhibited by PLpro.
Results: Here we show that PLpro also inhibits IRF3 activation at a step after phosphorylation and that this
inhibition is dependent on the de-ubiquitination (DUB) activity of PLpro. We found that PLpro is able to block the
type I IFN induction of a constitutively active IRF3, but does not inhibit IRF3 dimerization, nuclear localization or
DNA binding. However, inhibition of PLpro’s DUB activity by mutagenesis blocked the IRF3 inhibition activity of
PLpro, suggesting a role for IRF3 ubiquitination in induction of a type I IFN innate immune response.
Conclusion: These results demonstrate an additional mechanism that PLpro is able to inhibit IRF3 signaling. These
data suggest novel innate immune antagonism activities of PLpro that may contribute to SARS-CoV pathogenesis.
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The severe acute respiratory syndrome coronavirus
(SARS-CoV) emerged in 2002 from the Guangdong
Province in China [1,2]. The disease quickly spread
throughout the world, infecting more than 8,000 indivi-
duals and causing ~800 deaths. SARS-CoV caused sig-
nificant economic losses around the world, as air travel
was banned and/or limited in many affected regions. The
epidemic strain of SARS-CoV is no longer circulating in
the human population, however a strain of SARS-CoV po-
tentially able to infect humans is still found in bats in
China [3,4]. Additionally, many bat coronaviruses have
been found around the world, including North America* Correspondence: mfrieman@som.umaryland.edu
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unless otherwise stated.(Colorado [5], Maryland [6] and Canada [7]), Europe
(Germany [8]) and Africa (South Africa [9]) that have the
potential to become human pathogens. Importantly, a novel
Coronavirus has emerged in the Middle East, called the
Middle East respiratory syndrome coronavirus [10] (MERS-
CoV) that has currently infected 853 individuals in 22
countries, including Saudi Arabia, Qatar and Jordan, resul-
ting in 301 deaths as of October 2, 2014 (www.who.org).
MERS-CoV is phylogenetically grouped into the beta-
coronavirus lineage with SARS-CoV however it has been
defined as a sub-group displaying unique genomic cha-
racteristics including unique accessory proteins [11]. The
emergence of MERS-CoV has shown that, although
SARS-CoV may not re-emerge directly, other corona-
viruses are capable of emerging and causing significant re-
spiratory illness in humans.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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not stimulate a robust innate immune response in vitro
nor in vivo [12,13], perhaps explaining the significant
lung disease caused by SARS-CoV in humans and mice
in comparison to other human coronaviruses, which
usually only cause minor respiratory symptoms. We, and
others, have shown that SARS-CoV encodes several pro-
teins that block virus sensing and type I IFN signaling
pathways, resulting in a reduced innate immune re-
sponse [14-24]. The inhibition of the host response to
SARS-CoV leads to dampened production of host anti-
viral proteins, and thus resulting in higher viral loads,
more severe tissue damage, and enhanced lung patho-
logy in mouse models of SARS-CoV [25].
PLpro is a domain of the larger, virally encoded re-
plicase protein, called non-structural protein 3 or NSP3
[26]. PLpro cleaves specific sites in the ORF1ab poly-
protein to release the replicase proteins from the lon-
ger polypeptide to facilitate SARS-CoV replication. The
Papain-like Protease (PLpro) of SARS-CoV has been
previously described to inhibit the type I IFN signaling
pathway [16,18,19,23,27-30].
The induction of the innate immune response is key to
protecting a host from viral infection [31]. In the IFN
pathway, non-host RNA is sensed by several proteins in-
cluding retinoic acid-inducible gene 1 (RIG-I) and mela-
noma differentiation-associated protein 5 (MDA5), which
then signal through mitochondrial antiviral-signaling pro-
tein (MAVS) to activate IKK kinase epsilon (IKKi) and
Tank binding kinase 1 (TBK1) [32]. IKKi and TBK1 phos-
phorylate IRF3, leading to its dimerization, import into
the nucleus, and cooperation with other factors, to induce
expression of IFNβ. IFNβ is secreted, binds to neighboring
cells via the IFN alpha receptor I (IFNAR1), where it sig-
nals through the ISGF3 complex to induce several hun-
dred anti-viral proteins that can fortify the cell’s response
to infection.
In addition to PLpro’s protease activity, it has been
shown to have deubiquitination and de-ISGylation acti-
vities [16,18,28,29,33]. Studies on PLpro have shown that
it also inhibits host innate immune signaling by inhibit-
ing phosphorylation, dimerization and nuclear import of
IRF3 [16,18,28,29,33]. A recent report demonstrated that
PLpro interacts with stimulator of IFN genes (STING), a
scaffolding protein associated with the mitochondrial
membrane that interacts with IRF3, RIG-I, IKKi and
TBK1 [29]. By blocking phosphorylation of IKKi and
TBK1, PLpro interaction with STING prevents the sen-
sing of SARS-CoV RNA in the cell, and subsequent in-
duction of IFNβ.
It has been shown previously that PLpro can block
IRF3 phosphorylation [23]. We examined the inhibition
of IRF3 after phosphorylation using a constitutively ac-
tive phosphor-mimetic of IRF3, called IRF3(5D). We findthat PLpro is able to inhibit IRF3(5D) even though IRF3
(5D) can dimerize, be imported to the nucleus and bind
several type I IFN inducible promoters. By mutating the
active site of PLpro, we show that IRF3(5D) is no longer
deubiquitinated and can now induce IFNβ gene produc-
tion. These data demonstrate the multifunctional role of
PLpro in inhibiting the innate immune response and
suggests an additional role of PLpro during SARS-CoV
infection.
Materials and methods
Plasmids and cells culture
Firefly luciferase plasmids containing the IFN-β or NF-κB
promoter and the GFP- and HA-tagged SARS-CoV PLpro
expression plasmids were described previously [16]. The
SARS-CoV PLpro mutant used contains a double muta-
tion in the active site (C1651A and D1826A) as described
previously [17]. Flag-tagged IRF3(5D) was a gift from John
Hiscott (described in[34]). Ha-tagged Ubiquitin was pre-
viously described [16]. HEK293T cells were purchased
from ATCC (Catalog #CRL-3216) (Manassas, VA), grown
in DMEM (Invitrogen, Carlsbad, CA) with 10% FBS and
1% penicillin/streptomycin.
Luciferase assays
To analyze the induction of IFNβ induced genes, a lucifer-
ase reporter assay was used in HEK293T cells. Briefly, an
expression construct containing the luciferase ORF and the
IFNβ promoter (IFNβ/luciferase) was co-transfected with
either a GFP control plasmid or the designated PLpro plas-
mid. Transfections of reporter plasmids into HEK293Tcells
were performed with the Lipofectamine LTX (Invitrogen)
transfection reagent as directed by the manufacturer. For
all transfections, 10 ng of Renilla luciferase, 200 ng of
luciferase plasmid, 200 ng of viral expression plasmid,
200 ng of inducer plasmid (total 600 ng/well) was used in
each well of a 48 well plate with 1ul of Lipofectamine
LTX. For control wells that contained only the inducer
and luciferase plasmid and did not contain 600 ng plas-
mids in total, the remaining DNA was filled with an empty
GFP plasmid so we could assess transfection efficiency
and so that all transfections contained the same amount
of plasmid DNA. All transfections were performed in
triplicate and the average of 3 experiments is shown in
figures. At 18 hours post transfection cells were lysed and
assayed for luciferase expression using the Dual Luciferase
Reporter assay (Promega Inc). The ratio of experimental
treatment to control inducer after normalization to Renilla
luciferase was graphed in each figure.
Ubiquitination and immunoprecipitations
Plasmids vectors containing HA and FLAG tags ligated
to the C or N termini of the indicated ORFs were trans-
fected into HEK293T cells as described below. After
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fer (20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% NP-40),
the extract was centrifuged for 10 minutes at 4°C, and
the supernatant was removed. 25ul of washed EZ View
Red Anti-FLAG M2 Affinity Gel beads (Sigma, St Louis
MO, #F2426) were added to each extract and rotated
overnight at 4°C. Extract was then washed 3 times with
lysis buffer and re-suspended in SDS PAGE loading buf-
fer before boiling and electrophoresis.
For ubiquitination or deubiquitination experiments,
the protocol above was followed with the addition of
HA-tagged ubiquitin (HA-Ub) or mutant ubiquitin plas-
mids. Mutant ubiquitin plasmids that are only able to be
ubiquitinated at either K48 or K63 were added to the
transfection experiments as described above. The mu-
tant and wildtype ubiquitin plasmids were previously
described [35].
Western blotting and antibodies
Expression plasmids were assayed for protein expression
by Western blotting. Lysates were then run on SDS-PAGE
gels (NuPage, Invitrogen) and blotted to PVDF membrane
(Invitrogen). Proteins were visualized using anti-GFP anti-
body (G1544, Sigma Aldrich), anti-HA (Sigma H3663),
anti-Flag (Sigma F7425), HRP-conjugated secondary anti-
rabbit antibody (NA934, GE Life Sciences) and HRP-
conjugated secondary anti-rabbit antibody (NA931, GE
Life Sciences).
IRF3 Dimer gels
IRF3 dimer gels were performed as described in Iwamura
et al. [36] with the following alteractions. All buffers were
made 24 hours in advance and chilled overnight at 4°C.
Tris/Glycine running buffer was supplemented with 0.3 g
Sodium Deoxycholate. Native gels (Biorad Ready gel) was
pre-run for 30 minutes at 150 V before loading samples.
Native PAGE gels were run at 10 V for 2.5 hours before
soaking gel in running buffer for 30 minutes and trans-
ferring to PVDF for 90 minutes. An IRF3 and IRF3(5D)
sampled was boiled in SDS/PAGE loading dye for 5 mi-
nutes before loading as a monomer control. Proteins were
visualized with anti-Flag antibody (Sigma F7425) and anti-
HA antibody (Sigma H3663).
Electrophoretic mobility shift assay
Binding assays were performed with ten micrograms of
whole cell extracts incubated in a total volume of 15 μL
with buffer containing 50 mM HEPES (pH 7.9), 10% gly-
cerol, 200 mM KCl, 5 mM EDTA (pH 8), 1 mM MgCl2,
5 mM DTT, and 1 μg of poly (deoxyinosine-deoxycytidylic)
acid sodium salt (Sigma-Aldrich) to eliminate non-specific
binding. Samples were incubated on ice for 10 min, fol-
lowed by the addition of 150,000 CPU of 32P-labeled DNA
probe and 20 min of incubation at room temperature.Oligonucleotide probes corresponding to the ISREs of
ISG15 and OAS were annealed to their complementary
oligonucleoides using annealing buffer containing 100 mM
NaCl and 50 mM HEPES (pH 7.6). Forward sequences for
probes used:Oas1b ISRE: TTCCCGGGAAATGGAAACT
GAAAGTCCCAT,ISG15 ISRE: GATCGGAAAGGGAAA
CCGAAACTGAAGCC. T4 PNK (New England Biolabs)
was used to end-label annealed probes with γ32ATP.
Samples were electrophoresed at 180 Volts in 0.5%
Trisborate-EDTA buffer on a 5% native polyacrylamide gel
composed of 49:1 acrylamide to bis-acrylamide. Gels were
dried on Whatman paper at 80°C for 1 h and exposed by
autoradiogram.Chromatin immunoprecipitations
Chromatin immunoprecipitation (ChIP) analysis was per-
formed by using the Chromatin Immunoprecipitation
(ChIP) assay kit (Millipore, 17–295) and previously de-
scribed [25]. Briefly, HEK293T cells were transfected with
200 ng of each plasmid expressing either HA tagged
PLpro, Flag tagged IRF3 or Flag tagged IRF3(5D) singly or
in combination. At 24 hours post transfection, cells were
fixed, pelleted and immediately frozen at −80°C. For im-
munoprecipitation the pellets were lysed and sonicated,
with sonication conditions chosen to produce the desired
size distribution of chromatin, between 300 and 1,200 bp.
Lysates were immunoprecipitated with anti-IRF3 (Active
Motif, 39033), anti-Flag (Sigma, F7425), anti-acetyl-Histone
H3 (Millipore, 06–599) as a positive control, and anti-IgG
(Jackson Labs, 315-005-003) as a negative control. To af-
firm the presence or absence of specific IRF3-binding to
the IFNβ promoter following ChIP, PCR was performed.
Response-specific IFNβ promoter regions were amplified
by using the following primers: IFN-f 5’- GAATCCA
CGGATACAGAACCT-3’, IFN-r 5’-TTGACAACACGAA
CAGTGTCG-3’. The amplification of GAPDH served as
an input control (forward 5’-CATGGGGAAGTTGAA
GGTCG-3’, reverse 5’-TTGATGGTACATGACAAGGT
GC-3’). PCR products were run on a 1.5% agarose gel for
visualization.Immunofluorescence
GFP tagged PLpro, Flag tagged IRF3 and IRF3(5D) and
GFP plasmids were transfected into HeLa cells as de-
scribed above and cells fixed with 4% PFA. Fixed cells were
incubated with mouse anti-Flag M2 antibody (Sigma-
Aldrich, St. Louis MO). Cover-slips were incubated with
secondary antibodies; Alexa Fluor 546 conjugated goat
anti-mouse (Invitrogen, Carlsbad, CA). Fluorescence im-
aging was performed using a Zeiss Axioskop Microscope.
The IRF3 and IRF3(5D) localization assays were per-
formed in triplicate. Several fields of view were imaged for
each transfection experiment and representative images
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lization of IRF3 and IRF3(5D).
Results
SARS-CoV PLpro inhibits constitutively active IRF3(5D)
SARS-CoV PLpro has been shown to inhibit IRF3 phos-
phorylation, nuclear translocation and subsequent IFNβ
gene induction [16,23]. We sought to identify whether
PLpro acts at additional downstream targets to inhibit
IFNβ induction. To bypass the IRF3 phosphorylation step
in the signaling pathway, we used a constitutively active
phosphomimetic mutant of IRF3, called IRF3(5D). IRF3
(5D) has 5 of the C-terminal serine residues mutated to
aspartic acid (D), mimicking the C-terminal phospho-
rylated serine of active IRF3, bypassing the need for its
phosphorylation [34]. We hypothesized that, as PLpro in-
hibits IRF3 phosphorylation, IRF3(5D) would not have any
effect on the downstream activation of STING/IKK/IRF3
and allow us to analyze the effects of PLpro on IRF3 sig-
naling after its phosphorylation step.
To investigate this hypothesis, HEK293T cells were
transfected with the IFNβ/luciferase plasmid alone, or in
combination with a plasmid encoding IRF3(5D) (a potent
inducer of the IFNβ promoter) and either an empty ex-
pression plasmid or a plasmid expressing a HA-tagged
PLpro of SARS-CoV (Figure 1). We find that IRF3(5D) in-
duces ~60-fold higher levels of luciferase compared to
mock transfected cells and an empty GFP plasmid has no
effect on luciferase expression, as expected. However, ex-
pression of HA-tagged PLpro caused a strong inhibition
of IRF3(5D) dependent luciferase production. These data
demonstrates that PLpro is able to inhibit IRF3 induced
IFNβ gene induction at a post-phosphorylation step.
SARS-CoV PLpro does not inhibit IRF3(5D) dimerization
Upon phosphorylation, IRF3 homodimerizes before en-
tering the nucleus to induce IFN production. We hy-
pothesized that SARS-CoV PLpro may be blocking IRF3
(5D) dimerization to inhibit IFNβ induction. To this
end, HEK293T cells were transfected with Flag-tagged
IRF3 with and without SARS-CoV PLpro, and then in-
fected with Sendai Virus (SeV), a potent inducer of IRF3
activation and IFNβ induction, for six hours before all
cells were lysed and dimer formation assessed by SDS-
PAGE (Figure 2A) and native PAGE gel electrophoresis
(Figure 2B). As expected, in mock-infected cells, IRF3 is
found as a dimer, which is not changed during SeV in-
fection (Figure 2B) [37]. This is expected due to the pre-
vious finding that overexpression of IRF3 alone can
induce IFNβ gene induction. However, when HA-tagged
PLpro is co-transfected with IRF3, dimer formation is
inhibited (Figure 2B). This confirms the previous finding
that PLpro inhibits IRF3 phosphorylation, and thus its
dimerization [23].We performed the same assay on IRF3(5D)-transfected
cells, with and without HA-tagged PLpro. We performed
native PAGE on transfected HEK293T cells with a plasmid
expressing Flag-tagged IRF3(5D) alone or in combination
with HA-tagged PLpro (Figure 2C). We found that IRF3
(5D) readily dimerizes when over-expressed alone, and
PLpro has no effect on IRF3(5D) dimerization. These data
demonstrate that the inhibition of IRF3(5D)-dependent
IFNβ gene induction by PLpro is not due to PLpro bloc-
king IRF3(5D) dimerization.
PLpro does not block IRF3(5D) nuclear import
The next step after dimerization in IRF3 signaling is nu-
clear import. We, therefore, hypothesized that PLpro is
blocking nuclear import of IRF3(5D). To test this, we
transfected Vero E6 cells with either Flag-tagged IRF3
and IRF3(5D) with or without HA-tagged PLpro. As a
positive control, Flag-tagged IRF3 was transfected alone
and at 24 hours post transfection cells, were infected
with SeV for six hours. As expected, we found that prior
to SeV infection, IRF3 is localized primarily in the cyto-
plasm, and migrates to the nucleus upon SeV infection
(Figure 3A). When IRF3 and PLpro were co-transfected
in the presence of SeV, we found that IRF3 is only in the
cytoplasm. This demonstrates that PLpro most likely
blocks nuclear import of activated IRF3 (Figure 3A).
IRF3(5D) localized to both the nucleus and the cytoplasm
in transfected cells (Figure 3B), as previously reported [34],
reflecting the continuous cytoplasmic translation and nu-
clear import IRF3(5D). When PLpro is over-expressed,
IRF3(5D) is found in both the nucleus and the cytoplasm,
identical to what is found when IRF3(5D) is expressed
alone (Figure 3B). Therefore, we do not see a block of nu-
clear import of IRF3(5D) when PLpro is expressed. These
data demonstrate that PLpro is not blocking IRF3(5D) nu-
clear import to inhibit IFNβ gene induction.
PLpro does not block IRF3(5D) DNA binding activity
After activated IRF3 dimers are imported into the nu-
cleus, they bind to specific response elements in the pro-
moter region of IRF3-induced genes. Since PLpro does
not block IRF3(5D) nuclear import, we hypothesized
that it may block the ability of IRF3(5D) to bind to DNA
promoters. We hypothesized that PLpro may be inhibi-
ting the ability of IRF3 to bind to the DNA directly. Be-
cause PLpro is not found as a soluble protein in infected
cells, rather it is a domain of the larger NSP3 protein,
we would not hypothesize that PLpro would be binding
DNA natively. However, it is used as a comparator for
IRF3 binding to the promoter regions. In these experi-
ments, we assayed the ability of PLpro to affect IRF3
binding to DNA using two assays. First, we tested for
the ability of IRF3 to bind to the IFNβ promoter by per-
forming chromatin immuno-precipitation (ChIP) and
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Figure 1 SARS-CoV PLpro inhibits IRF3(5D) induction of IFNβ. A. Plasmid expressing SARS-CoV PLpro was tested for the ability to inhibit the
induction of an IFNβ promoter/luciferase reporter induced by IRF3(5D). The average induction with standard deviation across 3 transfections is
graphed relative to mock transfection. HEK293T cells were transfected with plasmids encoding IFNβ promoter/luciferase, Flag-tagged IRF3(5D),
empty GFP vector or HA-tagged SARS-CoV PLpro in the combinations noted. At 18 hours post-transfection cells were lysed and firefly luciferase
expression quantified. B. Lysate from each transfection in A was analyzed by western blot to assay protein expression of HA-tagged PLpro and
Flag-tagged IRF3(5D).
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http://www.virologyj.com/content/11/1/209second, we assayed for the ability of co-transfected
PLpro to inhibit IRF3 binding to other IFN-inducible
promoters by gel-mobility shift assay.
First, we performed ChIP of IRF3(5D) to identify
whether PLpro was altering the ability of IRF3(5D) to bind
the IFNβ promoter. HEK293T cells were transfected with
Flag-tagged IRF3 or Flag-tagged IRF3(5D) with or without
HA-tagged PLpro. At 24 hours post transfection, cells were
treated with paraformaldehyde (PFA) to cross-link protein
bound to DNA, lysed and sonicated to shear protein bound
chromatin for ChIP experiments. Immunoprecipitationwas performed against either IRF3, Flag or IgG (negative
control). The pre-ChIP input was scored for GAPDH to
control for the amount of template in the reactions
(Figure 4A). After immunoprecipitating the samples, the
crosslink was reversed and used for PCR with IFNβ pro-
moter primers spanning the IRF3 binding site (Figure 4B).
Negative controls of either untransfected protein or HA-
tagged PLpro transfected alone, showed no amplification
of the IFNβ promoter in immunoprecipitated samples,
demonstrating no background binding of PLpro to the
IFNβ promoter (Figure 4B). As expected, IFNβ promoter
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Figure 2 SARS-CoV PLpro does not inhibit IRF3(5D) dimer formation. The ability of SARS-CoV PLpro to inhibit IRF3(5D) dimer formation was
assayed using native PAGE gels. A. HEK293T cells were transfected with either Flag-tagged IRF3, HA-tagged PLpro or Flag-tagged IRF3(5D) in
combination or alone. For Flag-tagged IRF3 transfections, SeV was added at 18 hours post transfection for 6 hours before cells were lysed. 5ul of
total lysate was run on a SDS/PAGE gel to assay input lysate levels. B. Lysate from transfections in A were ran on Native PAGE gels for IRF3 dimer
visualization in the noted combinations of transfected plasmids, including a Flag-tagged IRF3 + SeV infected sample that was boiled before loading to
show monomer size. C. Lysate from transfections in A were ran on Native PAGE gels for IRF3(5D) dimer visualization in the noted combinations of
transfected plasmids, including a Flag-tagged IRF3(5D) that was boiled before loading to show monomer size. d = dimer, m =monomer.
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Figure 3 Effect of SARS-CoV PLpro on localization of IRF3 and IRF3(5D). Plasmids expressing either Flag-tagged IRF3, Flag-tagged IRF3(5D)
or HA-tagged PLpro were transfected alone or in combination into HeLa cells and visualized with anti-Flag or anti-HA antibody. A. Flag-tagged
IRF3 alone (left) or after SeV infection (middle), Flag-tagged IRF3 co-transfected with HA-tagged PLpro after SeV infection (right) B. Flag-tagged
IRF3(5D) alone (left), HA-tagged PLpro alone (middle) and Flag-tagged IRF3(5D) co-transfected with HA-tagged PLpro. All cells fixed in 4% PFA
and visualized with Alexa 488 conjugated anti-rabbit or Alexa 594 conjugated anti-mouse antibodies. Nuclei are delineated by white dashed lines.
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IRF3(5D) (Figure 4B, at arrow). To assess the effect of
PLpro on IRF3 binding activity, HA-tagged PLpro was co-
transfected with either Flag-tagged IRF3 or Flag-tagged
IRF3(5D). We found strong amplification of the IFNβ pro-
moter in each case (Figure 4C), suggesting that PLpro had
no effect on IRF3 or IRF3(5D) binding to the IFNβ pro-
moter. These data demonstrate that the inhibition of IRF3
(5D) by PLpro is not due to inhibition of IRF3(5D) binding
to the IFNβ promoter.
Electro-mobility Shift Assays (EMSA) were used to
test whether IRF3(5D) from cells containing both IRF3
(5D) and PLpro was able to bind to the ISG15 or OAS1b
promoter, both of which are bound by IRF3 during in-
fection. In this assay, HEK293T cells were transfected
with either empty plasmid, Flag-tagged IRF3(5D), HA-
tagged PLpro or Flag tagged IRF3(5D) and HA-tagged
PLpro together. Protein lysates were incubated with
radiolabeled oligonucleotide probes that correspond to
the ISG15 and OAS1 promoters. The negative control
lysate from HA tagged PLpro transfected cells did not
bind to either probe. However, supershifts, designating a
protein-DNA complex, were visible for both ISG15 and
OAS1 promoter elements in lysates containing IRF3(5D)
(Figure 4D). Interestingly, lysate from cells containing both
HA-tagged PLpro and Flag-tagged IRF3(5D) still bound to
the promoter elements of both genes (Figure 4D). These
data suggest that PLpro does not affect the ability of acti-
vated IRF3 to bind its DNA targets.IRF3(5D) activity is dependent on the de-ubiquitination
activity of PLpro
IRF3 has not been conclusively shown to be ubiquiti-
nated. Other proteins in the IRF3 signaling pathway,
such as RIGI-I [38], are ubiquitinated and can effect
IRF3 activation. We examined whether ubiquitination
of IRF3 is necessary for IRF3- dependent induction of
IFNβ. We then sought to identify whether the ubiquiti-
nation of IRF3(5D) was affected by PLpro. PLpro con-
tains de-ubiquitination (DUB) enzymatic activity and we
tested whether IRF3(5D) was de-ubiquitinated by PLpro.
We transfected HEK293T cells with either wildtype ubi-
quitin (Ub) tagged with HA (HA-Ub), K48-linked Ub
(K48-Ub), or K63-linked Ub (K63-Ub) with and without
Flag-tagged IRF3(5D) (Figure 5A). As expected, we ob-
served a ladder of ubiquitinated proteins when probed
with anti-HA in the lanes containing IRF3(5D) with
either of the HA-tagged Ub variants or HA-tagged Ub
variants alone. When Flag-tagged IRF3 and HA-tagged
Ub were co-transfected with GFP-tagged PLpro we
found that overall ubiquitinated protein levels were re-
duced (Figure 5A). Interestingly, K48-Ub and K63-Ub
plasmid transfections displayed higher levels of ubiquiti-
nated proteins compared to wildtype HA-Ub. For this
reason, K48-Ub and K63-Ub were solely used in im-
munoprecipitation experiments in Figure 5B. However,
wildtype HA-Ub does show reduced ubiquitinated pro-
tein levels when PLpro is co-expressed, identical to the
results with K48-Ub and K63-Ub plasmid transfections.
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Figure 4 SARS-CoV PLpro does not inhibit IRF3 or IRF3(5D) binding to the IFNβ promoter. A-C. Chromatin immunoprecipitations (ChIP)
were performed on HEK293T cells transfected with either HA tagged PLpro, Flag-tagged IRF3, Flag-tagged IRF3(5D) or the noted combinations. At
24 hours post transfection, cells were fixed with 4% Paraformaldehyde and DNA was extracted and sonicated to ~300-1.2Kb in length. Samples
were then immunoprecipitated with the designated antibodies and used as template for PCR reactions for GAPDH to control for input template
(A, arrow denotes correct PCR product) of the IFNβ promoter (B and C, arrows denote correct PCR products). PCR reactions were run on 2%
agarose gels to visualize products. D. HEK293T cells were transfected with either Flag-tagged IRF3(5D) alone or in combination with HA-tagged
PLpro. Cells were lysed and lysates incubated with radioactively labeled probe from either the ISG15 promoter or the OAS1b promoter. Samples
were run on a polyacrylamide gel and protein complexes visualized on film. Arrow denotes supershifted complex.
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Flag-tagged IRF3(5D) from selected lysate shown in
Figure 5A, we found that IRF3(5D) is ubiquitinated.
Interestingly, when co-transfected with PLpro and K48
and K63 ubiquitin, there is only minor ubiquitination of
IRF3(5D) (Figure 5B). These data demonstrate that IRF3
(5D) is ubiquitinated and that PLpro is able to deubiqui-
tinate IRF3(5D) in vitro.α−HA
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Figure 5 IRF3(5D) is deubiquitinated by SARS-CoV PLpro. Plasmids exp
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when transfected with HA-tagged K48 or K63 Ubiquitin, however when PLproWe hypothesized that the ubiquitination of IRF3(5D)
was necessary for its activity, as has been shown for
IRF3 [39], so we mutated the active site of PLpro to re-
move its deubiquitination activity [28]. To confirm the
inhibition of the DUB activity, HEK293T cells were
transfected with either a GFP-only plasmid, HA-tagged
Ub alone or HA-tagged Ub in combination with either
wild type PLpro (PLpro/wt) or active site mutant PLprom
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Figure 6 IRF3(5D) activity is dependent on the de-ubiquitination
activity of PLpro. A. HEK293T cells were transfected with either
empty plasmid, HA-tagged Ubiquitin alone or HA-tagged Ubiquitin in
combination with either wildtype PLpro (PLpro/wt) or active site mutant
PLpro (PLpro/mt). At 24 hours post-transfection, lysate was extracted
and analyzed by western blot with anti-HA and anti-GFP antibodies to
confirm that the PLpro/mt was unable to deubiquitinate cellular
proteins. B. Plasmid expressing SARS-CoV PLpro/wt and PLpro/mt were
tested for the ability to inhibit the induction of an IFNβ promoter/luciferase
reporter induced by IRF3(5D). The average induction with standard
deviation across 3 transfections is graphed relative to mock transfection.
HEK293T cells were transfected with plasmids encoding IFNβ promoter/
luciferase, Flag-tagged IRF3(5D), empty GFP vector, HA-tagged SARS-CoV
PLpro/wt or PLpro/mt in the combinations noted. At 18 hours post-
transfection cells were lysed and firefly luciferase expression quantified.
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http://www.virologyj.com/content/11/1/209(PLpro/mt) (Figure 6A). As before, both PLpro plasmids
are expressed as C-terminal GFP fusion proteins. We
observe that when HA-tagged Ub is transfected alone, a
large smear of ubiquitinated proteins are seen by western
blot. When GFP-tagged WT PLpro was co-transfected
with HA-tagged Ub, we observe a marked reduction in the
amount of ubiquitinated proteins. When the mutant GFP-
tagged PLpro is co-transfected with HA-tagged Ub the
smear of ubiquitinated proteins reappeared (Figure 6A),
demonstrating that the mutant PLpro no longer contains
deubiquitinase activity.
We used this mutant PLpro to assay for its ability to
inhibit IRF3(5D)-dependent induction of IFNβ/luciferase
reporter plasmid. As seen previously, when either IRF3
or IRF3(5D) are transfected into HEK293T cells with the
IFNβ/lux reporter we observe strong induction of lu-
ciferase (32-fold and 21-fold, respectively) (Figure 6B).
Also, as observed previously, when wildtype PLpro is co-
transfected with both we find that IFNβ/lux induction is
significantly inhibited. However, when the deubiquitination-
deficient mutant PLpro is transfected with either IRF3
or IRF3(5D) we found that there is no longer an inhib-
ition of IFNβ/lux induction. These data demonstrate
that the deubiquitination activity of PLpro is responsible
for limiting gene induction of IRF3(5D) on the IFNβ
promoter.
Discussion
The innate immune response is the first pathway in the
cell to detect a virus during infection and many viru-
ses express proteins that actively inhibit this res-
ponse [31,40]. SARS-CoV expresses several proteins that
inhibit various innate immune sensing and response
pathways [14-24]. We and others have shown that
SARS-CoV PLpro blocks the innate sensing pathway by
inhibiting IRF3 activation [16,23] through binding to
STING [29]. In this work, we show that PLpro can act
downstream of STING to block IRF3’s function as a
transcription factor in the nucleus. PLpro is a domain of
the larger NSP3 protein. In our studies a soluble PLpro
form is assessed for its function in inhibiting IRF3 sig-
naling. During a natural infection, the PLpro domain of
NSP3 is localized on double membrane vesicles induced
by coronaviruses during infection, with the PLpro do-
main in a cytoplasmic loop of NSP3. The effect of PLpro
membrane localization during infection compared to the
soluble form used here and its role on the IRF3 pathway
is currently under investigation. Understanding the role
of PLpro in SARS-CoV pathogenesis is critical to fully
understand due to its central role as one of the two pro-
teases responsible for ORF1ab polyprotein cleavage and
its role as an IFN antagonist. The combined enzymatic
activities of PLpro make it a highly attractive target for
therapeutic inhibitor development.
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are necessary for SARS-CoV to cleave the coronavirus
ORF1A polyprotein into separate peptides that function
in replication of SARS-CoV genomic RNA [26]. PLpro
has protease activity in vitro and in vivo while also con-
taining de-ubiquitination and de-ISGylation activity at
the same active site [18]. We, and others have shown
that PLpro inhibits IRF3 activation by blocking phos-
phorylation of IRF3 and subsequent induction of type I
IFN gene transcription [16,23]. We hypothesized that
PLpro could act to inhibit IRF3 using additional mecha-
nisms due to its de-ubiquitinase activity. To this end, we
analyzed the ability of PLpro to inhibit IRF3(5D), a phos-
phomimetic of IRF3 that replaces 5 serines (S) in the C
terminus of IRF3 to aspartic acid (D), thus mimicking
what phosphorylated and activated IRF3 [34]. IRF3(5D)
is highly active when transfected into cells and readily
induces interferon induced genes by binding to pro-
moter regions and inducing transcriptional induction.
When IRF3(5D) was expressed in a cell, it induced
the expression of IFNβ without any exogenous stimuli.
We were able to show that PLpro inhibits IRF3(5D)
dependent induction of IFNβ, suggesting that PLpro can
also inhibit IRF3 at a step after phosphorylation. We fur-
ther analyzed at which step PLpro inhibited the activity
of IRF3(5D); from dimerization of IRF3 to binding to
IFNβ gene promoter induction. We were able to demon-
strate that PLpro does not inhibit IRF3(5D) dimerization
in the cytoplasm, does not inhibit its nuclear import, or
the ability to bind to the IFNβ promoter or other pro-
moters of IRF3 inducible genes.
We hypothesized that IRF3(5D) is not correctly mo-
dified and thus unable to bind to the transcriptional
machinery. It has been shown that IRF3 needs to be ubi-
quitinated to be transcriptionally active. Using a cataly-
tically inactive PLpro mutant, we were able to show that
the deubiquitinase function of PLpro is required for in-
hibition of IRF3(5D) dependent induction of IFNβ.
Viral inhibitors of innate immunity are critical for viral
replication and pathogenesis. While many viral antago-
nists of IFN signaling have been identified, their mecha-
nisms of action are unclear. In this study we have
identified an additional role for PLpro in the inhibition of
IRF3 signaling. Since no viral immune antagonist can fully
inhibit its target, it is rational that a viral protein could
evolve to inhibit the same pathway at multiple steps.
SARS-CoV PLpro has been shown to inhibit IRF3 phos-
phorylation early in the type I IFN signaling pathway.
Here, we demonstrate that SARS-CoV PLpro is able to in-
hibit IRF3 dependent type I IFN activation at a later stage,
by deubiquitinating IRF3 and blocking its ability to induce
IFNβ transcription. This additional activity demonstrates
the important additional role that may be played by PLpro
in the pathogenesis of SARS-CoV.Competing interests
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